Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

DARK SECRETS: 9 | Rare Historical Photos

Pfizer and BioNTech launch clinical trial for Omicron-specific vaccine

Pfizer Inc and BioNTech have announced the start a clinical trial to test a new version of their vaccine specifically designed to target the Omicron variant of Covid-19 Omicron variant.

Evening Standard

Pfizer, BioNTech begin study of omicron-specific COVID vaccine

Pfizer Inc. said it is starting a study of a COVID-19 vaccine that targets the omicron variant, exploring its use in previously vaccinated younger and middle-aged adults as well as those who haven’t received another coronavirus shot.

Tribune News Service

Pfizer, BioNTech Launch Omicron-Targeted COVID-19 Vaccine Trial

Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) have

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Pfizer and BioNTech Launch Trial of Omicron-Targeted COVID Vaccine

Pfizer Inc and BioNTech SE said on Tuesday they started a clinical trial to test a new version of their vaccine specifically designed to target the COVID-19 Omicron variant, which has eluded some of the protection provided by the original two-dose vaccine regimen. The companies plan to test the immune…

Asharq Al-Awsat

The Daily Biotech Pulse: Pfizer-BioNTech Starts Omicron-Specific Vaccine Study, J&J Misses On Topline, Sierra Oncology Reports Positive Data

Here's a roundup of top developments in the biotech space over the last 24 hours.

Benzinga

Pfizer launches Omicron vaccine trial; UK reports highest daily deaths since February – as it happened

Company hopes vaccine will be ready for approval by March; UK reports 439 deaths and more than nearly 95,000 cases

The Guardian - UK

A Bearish Sign Appears On BioNTech's Chart

If history is any guide, there may be trouble ahead for shares of BioNTech (NASDAQ:BNTX). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

This Is What Whales Are Betting On BioNTech

A whale with a lot of money to spend has taken a noticeably bearish stance on BioNTech. Looking at options history for BioNTech (NASDAQ:BNTX) we detected 14 strange trades.

Benzinga

Where BioNTech Stands With Analysts

Within the last quarter, BioNTech (NASDAQ:BNTX) has observed the following analyst ratings:

Benzinga

1 … 6 7 8 9

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

International Monetary Fund

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.